Neovacs Overview

  • Founded
  • 1993
Founded
  • Status
  • Public
  • Employees
  • 15
Employees
  • Stock Symbol
  • ALNEV
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $0.01
  • (As of Tuesday Closing)

Neovacs General Information

Description

Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Contact Information

Website
www.neovacs.fr
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 3-5, Impasse Reille
  • 75014 Paris
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neovacs Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.01 $0.01 $25M 2.37B 127M -$0.07

Neovacs Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 34,219 5,402 19,141 32,577
Revenue 1 85 127 902
EBITDA (12,306) (10,235) (15,380) (20,471)
Net Income (11,280) (8,450) (12,722) (16,734)
Total Assets 2,205 8,541 8,280 14,332
Total Debt 5,230 169 334 3,153
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neovacs‘s full profile, request access.

Request a free trial

Neovacs Executive Team (8)

Name Title Board Seat Contact Info
Hugo Brugière Chief Executive Officer
Geraldine Grouard-Vogel Ph.D Chief Scientific Officer
Daniel Zagury Ph.D Founder & Board Member
Therese Croughs MD Chief Medical Officer
You’re viewing 4 of 8 executive team members. Get the full list »

Neovacs Board Members (10)

Name Representing Role Since
000000 000000 Self Board Member 000 0000
000000 000000 00.0 Neovacs Founder & Board Member 000 0000
0000000 0000000000 00.0 Neovacs Board Member 000 0000
0000-0000000 00000000 Self Chairman of the Board 000 0000
0000000 0000000 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Neovacs Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neovacs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Neovacs‘s full profile, request access.

Request a free trial

Neovacs Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 (0000 15-Nov-2016 000000000 00000 00 Buildings and Property 000000 000000
Neostell 19-Jul-2016 Joint Venture Pharmaceuticals 0000000 0000000 00.0
To view Neovacs’s complete investments history, request access »